Narrow-moat Quest Diagnostics DGX delivered second-quarter results that slightly exceeded our expectations on the top line, but that was offset by earnings that fell slightly short of our full-year ...
Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related to Alzheimer's disease in individuals with mild cognitive impairment (MCI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback